- Home
- CGAU vs NVCR Comparison
CGAU vs NVCR Comparison
Compare CGAU & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGAU
- NVCR
- Stock Information
- Founded
- CGAU 2002
- NVCR 2000
- Country
- CGAU Canada
- NVCR Switzerland
- Employees
- CGAU N/A
- NVCR N/A
- Industry
- CGAU Precious Metals
- NVCR Medical/Dental Instruments
- Sector
- CGAU Basic Materials
- NVCR Health Care
- Exchange
- CGAU Nasdaq
- NVCR Nasdaq
- Market Cap
- CGAU 1.6B
- NVCR 1.4B
- IPO Year
- CGAU N/A
- NVCR 2015
- Fundamental
- Price
- CGAU $9.25
- NVCR $12.15
- Analyst Decision
- CGAU Buy
- NVCR Buy
- Analyst Count
- CGAU 3
- NVCR 7
- Target Price
- CGAU $13.33
- NVCR $28.79
- AVG Volume (30 Days)
- CGAU 1.6M
- NVCR 1.3M
- Earning Date
- CGAU 10-30-2025
- NVCR 10-29-2025
- Dividend Yield
- CGAU 2.16%
- NVCR N/A
- EPS Growth
- CGAU N/A
- NVCR N/A
- EPS
- CGAU 0.33
- NVCR N/A
- Revenue
- CGAU $1,214,156,000.00
- NVCR $630,160,000.00
- Revenue This Year
- CGAU $6.05
- NVCR $6.68
- Revenue Next Year
- CGAU $9.39
- NVCR $7.01
- P/E Ratio
- CGAU $28.30
- NVCR N/A
- Revenue Growth
- CGAU N/A
- NVCR 14.58
- 52 Week Low
- CGAU $5.41
- NVCR $10.87
- 52 Week High
- CGAU $9.43
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- CGAU 77.96
- NVCR 46.57
- Support Level
- CGAU $8.61
- NVCR $11.98
- Resistance Level
- CGAU $9.01
- NVCR $12.83
- Average True Range (ATR)
- CGAU 0.24
- NVCR 0.56
- MACD
- CGAU 0.12
- NVCR 0.15
- Stochastic Oscillator
- CGAU 89.94
- NVCR 25.49
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.